AT1 Receptor Blocker Added to ACE Inhibitor Provides Benefits at Advanced Stage of Hypertensive Diastolic Heart Failure

Hypertension

Volumn 43, Issue 3, 2004, Pages 686-691

  Yoshida, Junichi ^a,b   Yamamoto, Kazuhiro ^a   Mano, Toshiaki ^a,b,c   Sakata, Yasushi ^a,b   Nishikawa, Nagahiro ^a,b   Nishio, Mayu ^a   Ohtani, Tomohito ^a   Miwa, Takeshi ^b   Hori, Masatsugu ^a   Masuyama, Tohru ^a,b,c  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Angiotensin II; Angiotensin converting enzyme; Diastole; Heart failure; Oxidative stress

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; OLMESARTAN; PLACEBO; REACTIVE OXYGEN METABOLITE; TEMOCAPRIL; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DETERIORATION; DIASTOLIC BLOOD PRESSURE; DIASTOLIC HEART FAILURE; DISEASE MODEL; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART MUSCLE RELAXATION; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; HYPERTENSION; INFLAMMATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE ACTIVATION; MALE; MUSCLE RIGIDITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BLOCKING; SALT INTAKE; SALT STRESS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CALCIUM-BINDING PROTEINS; CALCIUM-TRANSPORTING ATPASES; DIASTOLE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; EXTRACELLULAR MATRIX; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HEMODYNAMIC PROCESSES; HYPERTENSION; IMIDAZOLES; INFLAMMATION; MALE; RATS; RATS, INBRED DAHL; REACTIVE OXYGEN SPECIES; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; TETRAZOLES; THIAZEPINES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 10744227379     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000118017.02160.fa     Document Type: Article

References (39)

1. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, Redfield MM. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998;98:2282-2289.
2. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction. J Am Coll Cardiol. 1999;33:1948-1955.
3. Doi R, Masuyama T, Yamamoto K, Doi Y, Mano T, Sakata Y, Ono K, Kuzuya T, Hirota S, Koyama T, Miwa T, Hori M. Development of different phenotypes of hypertensive heart failure: systolic versus diastolic failure in Dahl salt-sensitive rats. J Hypertens. 2000;18:111-120.
4. Masuyama T, Yamamoto K, Sakata Y, Doi R, Nishikawa H, Kondo H, Ono K, Kuzuya T, Sugawara M, Hori M. Evolving changes in Doppler mitral flow velocity pattern in rats with hypertensive hypertrophy. J Am Coll Cardiol. 2000;36:2333-2338.
5. Sakata Y, Masuyama T, Yamamoto K, Doi R, Mano T, Kuzuya T, Miwa T, Takeda H, Hori M. Renin angiotensin system-dependent hypertrophy as a contributor to heart failure in hypertensive rats: different characteristics from renin angiotensin system-independent hypertrophy. J Am Coll Cardiol. 2001;37:293-299.
6. Kim S, Yoshiyama M, Izumi Y, Kawano H, Kimoto M, Zhan Y, Iwao H. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation. 2001;103:148-154.
7. Philbin EF, Rocco TA, Jr., Lindenmuth NW, Ulrich K, Jenkins PL. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med. 2000;109:605-613.
8. Chen HH, Lainchbury JG, Senni M, Bailey KR, Redfield MM. Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria. J Card Fail. 2002;8:279-287.
9. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
10. McMurray JJV, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-771.
11. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Ostergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777-781.
12. Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Miwa T, Hori M, Masuyama T. Temocapril prevents transition to diastolic heart failure in rats even if initiated after appearance of LV hypertrophy and diastolic dysfunction. Cardiovasc Res. 2003;57:757-765.
13. Sakata Y, Masuyama T, Yamamoto K, Nishikawa N, H. Y., Kondo H, Ono K, Otsu K, Kuzuya T, Miwa T, Takeda H, Miyamoto E, Hori M. Calcineurin inhibitor attenuates left ventricular hypertrophy leading to prevention of heart failure in hypertensive rats. Circulation. 2000;102:2269-2275.
14. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Yoshida J, Miwa T, Sugawara M, Yamaguchi Y, Ookawara T, Suzuki K, Hori M. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res. 2002;55:76-82.
15. Nishikawa N, Yamamoto K, Sakata Y, Mano T, Yoshida J, Miwa T, Takeda H, Hori M, Masuyama T. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovasc Res. 2003;57:766-774.
16. Yoshida J, Yamamoto K, Mano T, Sakata Y, Nishikawa N, Miwa T, Hori M, Masuyama T. Angiotensin II type 1 and endothelin type A receptor antagonists differently modulate extracellular matrix regulatory system in diastolic heart failure. J Hypertens. 2003;21:437-444,
17. Nakamura K, Kusano K, Nakamura Y, Kakishita M, Ohta K, Nagase S, Yamamoto M, Miyaji K, Saito H, Morita H, Emori T, Matsubara H, Toyokuni S, Ohe T. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation. 2002;105:2867-2871.
18. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part II causal mechanisms and treatment. Circulation. 2002;105:1503-1508.
19. Weber KT. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation. 1997;96:4065-4082.
20. Weber KT. Targeting pathological remodeling: concepts of cardioprotection and reparation. Circulation. 2000;102:1342-1345.
21. Varagic J, Frohlich ED. Local cardiac renin-angiotensin system: hypertension and cardiac failure. J Mol Cell Cardiol. 2002;34:1435-1442.
22. Varo N, Etayo J, Zalba G, Monrea LI, Diez J. Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens. 1999;17:107-114.
23. Dahlof B, Zanchetti A, Diez J, Nicholls MG, Yu CM, Barrios V, Aurup P, Smith RD, Johansson M. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens. 2002;20:1855-1864.
24. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002;105:2512-2517.
25. Spinale FG, de Gasparo M, Whitebread S, Hebbar L, Clair MJ, Melton M, Krombach S, Mukherjee R, Iannini JP, O SJ. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: 1. effects on left ventricular performance and neurohumoral systems. Circulation. 1997;96:2385-2396.
26. Mankad S, d'Amato TA, Reichek N, McGregor WE, Lin J, Singh D, Rogers WJ, Kramer CM. Combined angiotensin II receptor antagonism and angiotensin-converting enzyme inhibition further attenuates postinfarction left ventricular remodeling. Circulation. 2001;103:2845-2850.
27. Nakamura Y, Yoshiyama M, Omura T, Yoshida K, Izumi Y, Takeuchi K, Kim S, Iwao H, Yoshikawa J. Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction. Cardiovasc Res. 2003;57:48-54.
28. Haller H, Behrend M, Park JK, Schaberg T, Luft FC, Distler A. Monocyte infiltration and c-fms expression in hearts of spontaneously hypertensive rats. Hypertension. 1995;25:132-138.
29. Shioi T, Matsumori A, Kihara Y, Inoko M, Ono K, Iwanaga Y, Yamada T, Iwasaki A, Matsushima K, Sasayama S. Increased expression of interleukin-1beta and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload. Circ Res. 1997;81:664-671.
30. Nicoletti A, Michel JB. Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc Res. 1999;41:532-543.
31. Kuwahara F, Kai H, Tokuda K, Niiyama H, Tahara N, Kusaba K, Takemiya K, Jalalidin A, Koga M, Nagata T, Shibata R, Imaizumi T. Roles of intercellular adhesion molecale-1 in hypertensive cardiac remodeling. Hypertension. 2003;41:819-823.
32. Schultz JEJ, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, Kimball TR, Doetschman T. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest. 2002;109:787-796.
33. Thaik CM, Calderone A, Takahashi N, Colucci WS. Intrleukin-1beta modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest. 1995;96:1093-1099.
34. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation. 2002;106:130-135.
35. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91:988-998.
36. Fukuzawa M, Satoh J, Sagara M, Muto G, Muto Y, Nishimura S, Miyaguchi S, Qiang XL, Sakata Y, Nakazawa T, Ikehata F, Ohta S, Toyota T. Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo. Immunopharmacology. 1997;36:49-55.
37. Usui M, Egashira K, Tomita H, Koyanagi M, Katoh M, Shimokawa H, Takeya M, Yoshimura T, Matsushima K, Takeshita A. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation. 2000;101:305-310.
38. Liu J, Yang F, Yang XP, Jankowski M, Pagano PJ. NAD(P)H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy. Arterioscler Thromb Vasc Biol. 2003;23:776-782.
39. Hirotani S, Otsu K, Nishida K, Higuchi Y, Morita T, Nakayama H, Yamaguchi O, Mano T, Matsumura Y, Ueno H, Tada M, Hori M. Involvement of nuclear factor-kB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation. 2002;105:509-515.